Monday, January 28, 2019
Eiger BioPharmaceuticals initiated at Baird
Eiger BioPharmaceuticals initiated with an Outperform at Baird. Baird analyst Madhu Kumar started Eiger BioPharmaceuticals with an Outperform rating and $47 price target. The company’s hepatitis delta virus pipeline could transform the disease, with lonafarnib monotherapy in progeria can provide near-term, high EBIT margin revenue, Kumar tells investors in a research note.
https://thefly.com/landingPageNews.php?id=2854739
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.